# Clasp Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clasp-therapeutics

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.clasptx.com
- Total disclosed funding: $72M
- Latest round: Series A (Oct 10, 2023)
- Investors on record: 9

## About

Based in Maryland, US, and founded in 2020, Clasp Therapeutics operates as a biotechnology company focused on immuno-oncology for cancer patients. In March 2024, Clasp Therapeutics raised USD 150 million in series A funding co-led by Catalio Capital Management, Third Rock Ventures, and Novo Holdings, with participation from Vivo Capital, Cure Ventures, Blackbird Ventures, etc.

Clasp Therapeutics is revolutionizing immuno-oncology with next-generation T cell engagers (TCEs), focusing on creating precision medicines to treat cancers that don't respond to current treatments. The company goal is on developing personalized treatments that use the immune system to identify and kill cancers with common driver mutations across cancer types. Clasp's technique targets modification protein fragments found in cancer cells, a concept that has the potential to significantly expand the reach of current immuno-oncology medicines by targeting cancer-driving proteins inside cells that were previously invisible to similar drugs.

The company plans to use the March 2024 funding to support the expansion and development of its product.

## Funding rounds

- Series A, Oct 10, 2023, $72M — Alexandria Venture Investments, Novo Holdings, Vivo Capital, Third Rock Ventures, Blackbird Ventures, Pictet Alternative Advisors, BrightEdge Ventures, Catalio Capital Management, Cure Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Novo Holdings — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Blackbird Ventures (https://capitalatlas.ai/funds/blackbird-ventures) — Series A
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series A
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- Cure Ventures (https://capitalatlas.ai/funds/cure-ventures) — Series A